嘉事堂药业股份有限公司 关联交易管理办法 （2025 年修订） 2025 年 9 月 17 日 北京 经 2025 年第三次临时股东会审议通过 | 第一章 | 总则 | | 1 | | --- | --- | --- | --- | | 第二章 | 关联交易和关联人 | | 2 | | 第三章 | 关联交易的管理及审议程序 | | 4 | | 第四章 | 关联交易的信息披露 | | 9 | | 第五章 | 附则 | 12 | | 第一章 总则 第一条 为进一步加强嘉事堂药业股份有限公司（以下简称"公 司"）关联交易管理，明确管理职责和分工，维护公司股东和债权人 的合法利益，特别是中小投资者的合法利益，保证公司与关联人之间 订立的关联交易合同符合公平、公开、公允的原则，根据《中华人民 共和国公司法》《中华人民共和国证券法》《上市公司信息披露管理办 法（2021 修订）》《深圳证券交易所股票上市规则》（以下简称"《股 票上市规则》"）《深圳证券交易所上市公司自律监管指引第 7 号—— 交易与关联交易》《企业会计准则》、本公司《章程》的有关规定以及 财政部、中国人民银行、中国证券监督管理委员会（以下简称"中国 证监 ...

关于嘉事堂药业股份有限公司 2025 年第三次临时股东会的法律意见书 文件编号：安理法意（2025）嘉字第 091701 号 致：嘉事堂药业股份有限公司 北京市安理律师事务所（以下简称"本所"）接受嘉事堂药业股份有限公司 （以下简称"嘉事堂"或"公司"）委托，指派张晓光律师、王瑞欣律师（以下 简称"承办律师"）担任嘉事堂药业股份有限公司于 2025 年 9 月 17 日召开的 2025 年第三次临时股东会（以下简称"本次股东会"）特别法律顾问，出席会 议，并出具本法律意见书。 本法律意见书系依据《中华人民共和国证券法》（以下简称"证券法"）、 《中华人民共和国公司法》（以下简称"公司法"）、中国证券监督管理委员会 《上市公司股东会规则》（以下简称"股东会规则"）、《深圳证券交易所股票 上市规则》等规范性文件及《嘉事堂药业股份有限公司章程》（以下简称"公司 章程"），并结合《嘉事堂药业股份有限公司第七届董事会第十八次会议决议的 公告》及《嘉事堂药业股份有限公司关于召开 2025 年第三次临时股东会的通知 公告》而出具。 第一节 律师声明 1. 本法律意见书仅对出具日以前与本次股东会有关的问题发表意见，并不 对有 ...

嘉事堂药业股份有限公司 2025年第三次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1．本次股东会未出现否决提案的情形。 2．本次股东会未涉及变更以往股东会已通过的决议。 证券代码：002462 证券简称：嘉事堂 公告编号：2025-36 一、会议召开和出席情况 （一）嘉事堂2025年第三次临时股东会于2025年9月17日下午3点在公司二楼 会议室召开。会议由公司董事长徐曦先生主持，本次股东会按照会议议程，采用 现场表决与网络投票相结合的表决方式，审议了相关议案并作出决议。本次股东 会的召开符合《公司法》和《公司章程》的有关规定，会议召开合法有效。 （二）会议出席情况 1. 股东出席的总体情况： 通过现场和网络投票的股东153人，代表股份120,825,068股，占公司有表决 权股份总数的41.4200％。 （1）通过现场投票的股东8人，代表股份117,649,775股，占公司有表决权 股份总数的40.3315％。 （2）通过网络投票的股东145人，代表股份3,175,293股，占公司有表决权 股份总数的1.0885％。 2 ...

证券日报网讯嘉事堂9月16日在互动平台回答投资者提问时表示，公司目前聚焦于药品、医疗器械的批 发配送、专业药械物流及医药零售等主营业务，致力于为医疗机构、下游经销商及终端消费者提供高品 质的医药健康产品与服务。公司现有业务包含创新药销售业务。 （文章来源：证券日报） ...

（文章来源：证券日报） 证券日报网讯嘉事堂9月16日在互动平台回答投资者提问时表示，公司康复业务处于试点阶段，在探索 中积累经验。公司将继续聚焦主责主业，在医药流通过程中推进固链、强链、延链。 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.29% on September 10, with Dazhenglin leading the drop [1] - The Shanghai Composite Index closed at 3812.22, up 0.13%, while the Shenzhen Component Index closed at 12557.68, up 0.38% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with Seer Medical (603716) rising by 3.99% to a closing price of 28.70, and Dazhenglin (603233) falling by 2.37% to 17.30 [1][2] - Other notable gainers included Guofa Co. (600538) with a 1.65% increase and Dazhangzhang (002462) with a 1.22% increase [1] Trading Volume and Value - Seer Medical had a trading volume of 250,500 shares and a transaction value of 719 million yuan, while Dazhenglin had a trading volume of 77,200 shares and a transaction value of 134 million yuan [1][2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 11.87 million yuan from institutional investors and 50.86 million yuan from speculative funds, while retail investors contributed a net inflow of 62.74 million yuan [2] - Specific stocks like Seer Medical and Jiuzhoutong (600998) had significant net inflows from institutional investors, while others like Yifeng Pharmacy (603939) experienced net outflows from both institutional and speculative funds [3]

Group 1 - The company, Jia Shi Tang (002462), clarified on September 5 that it is currently not involved in any retail department store-related business [1]

Core Insights - The company, Jia Shi Tang, reported a significant decline in net profit by 36.24% year-on-year for the first half of 2025, with total revenue decreasing by 24.45% to 9.699 billion yuan [1] - The second quarter of 2025 saw a revenue of 5.021 billion yuan, down 6.94% year-on-year, and a net profit of 611.14 million yuan, down 34.06% year-on-year [1] Financial Performance - Total revenue for the first half of 2025 was 9.699 billion yuan, compared to 12.839 billion yuan in the same period of 2024, reflecting a decrease of 24.45% [1] - The net profit attributable to shareholders was 1.07 billion yuan, down from 1.68 billion yuan in 2024, marking a decline of 36.24% [1] - The gross profit margin improved to 6.32%, an increase of 4.03% year-on-year, while the net profit margin decreased to 1.68%, down 14.88% [1] - Total expenses (selling, administrative, and financial) amounted to 322 million yuan, representing 3.32% of revenue, a decrease of 13.01% year-on-year [1] - Earnings per share fell to 0.37 yuan, down 36.21% from 0.58 yuan in 2024 [1] - Operating cash flow per share increased significantly to 1.55 yuan, a rise of 314.45% year-on-year [1] Asset and Liability Management - Cash and cash equivalents increased by 30.16% to 2.23 billion yuan, indicating a healthy cash position [1] - Accounts receivable decreased by 15.51% to 6.512 billion yuan, suggesting improved collection efficiency [1] - Interest-bearing debt reduced by 18.37% to 2.357 billion yuan, reflecting better debt management [1] Return on Investment - The company's Return on Invested Capital (ROIC) for the previous year was 4.54%, indicating weak capital returns [3] - The historical median ROIC over the past decade was 9.42%, with the lowest recorded ROIC in 2024 at 4.54% [3] - The net profit margin for the previous year was 1.34%, suggesting low added value in products or services [3] Cash Flow and Receivables - The cash flow situation is a concern, with cash assets covering only 69.79% of current liabilities, and the average operating cash flow over the past three years covering only 16.82% of current liabilities [3] - Accounts receivable have reached 4053.3% of profit, indicating potential issues in receivables management [3]

Group 1 - The company, Jiashitang, announced the convening of its 18th meeting of the 7th Board of Directors on August 29, 2025, to review the semi-annual report and summary for 2025 [1] - For the first half of 2025, Jiashitang's revenue composition was as follows: pharmaceutical wholesale accounted for 96.12%, pharmaceutical retail for 3.18%, and pharmaceutical logistics for 0.7% [1]

Core Viewpoint - The company reported a significant decline in both revenue and net profit for the first half of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first half of 2025 was 9.699 billion yuan, representing a year-on-year decrease of 24.45% [1] - The net profit attributable to shareholders of the listed company was 107 million yuan, down 36.24% year-on-year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 96.2624 million yuan, a decrease of 9.84% year-on-year [1] - The basic earnings per share were 0.37 yuan [1]